SCHEMBL7951874

SCHEMBL7951874

O=C(CCC(C(=O)NO)S(=O)(=O)c1ccccc1Br)NO

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLCG1 P19174 1/20 0.40
MMP9 P14780 4/20 0.39
MMP13 P45452 4/20 0.39
MMP1 P03956 3/20 0.39
MMP2 P08253 2/20 0.39
MMP12 P39900 2/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
MMP3 P08254 1/20 0.39
MMP8 P22894 1/20 0.39
MMP14 P50281 1/20 0.39
MMP16 P51512 1/20 0.39
RECQL P46063 1/20 0.38
HDAC2 Q92769 4/20 0.38
HDAC8 Q9BY41 3/20 0.38
HDAC6 Q9UBN7 3/20 0.38
HDAC3 O15379 2/20 0.38
HDAC4 P56524 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7696804 0.84 BMP1 (0.43) MMP9MMP13MMP1MMP2MMP12
SCHEMBL6929547 0.81 MMP7 (0.52) MMP9MMP1MMP2MMP14HDAC8
SCHEMBL7394460 0.77 MMP9 (0.37) PLCG1MMP9MMP13MMP1MMP2
SCHEMBL6932142 0.77 MMP9 (0.51) MMP9MMP13MMP1MMP2CA1
SCHEMBL6934202 0.72 MMP13 (0.53) MMP9MMP13MMP1MMP2MMP12
SCHEMBL4432528 0.64 CA1 (0.52) PLCG1CA1CA2CA4CA6
SCHEMBL15918007 0.64 CA2 (0.52) PLCG1CA1CA2CA4CA6
SCHEMBL7324090 0.64 MMP13 (0.71) MMP9MMP13MMP1MMP2MMP12
SCHEMBL1800130 0.63 CA1 (0.56) PLCG1CA1CA2CA4CA6
SCHEMBL1767645 0.63 CA1 (0.56) PLCG1MMP9MMP13MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6331563-B1 LOW MOLECULAR WEIGHT, NON-PEPTIDE INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME; TREATING ARTHRITIS, TUMOR METASTASIS, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, INSULIN RESISTANCE WYETH HOLDINGS CORPORATION 2001-12-18 US disclosed